- Compass Pathways plc CMPS has announced results from Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression.
- The study has achieved its primary endpoint for the highest dose, with a 25mg dose of COMP360 demonstrating a highly statistically significant and clinically relevant reduction in depressive symptom severity after three weeks, with rapid and durable treatment response.
- The 10mg vs. 1mg dose did not show a statistically significant difference at week 3.
- At least twice the number of patients in the 25mg group showed a response and remission at week 3 and week 12, compared with the 1mg group.
- COMP360 was generally well tolerated, with more than 90% of treatment-emergent adverse events being mild or moderate in severity.
- The Company plans to start a pivotal phase 3 program in 2022.
- Compass posted a Q3 EPS loss of $(0.38) higher than $(1.30) a year ago.
- Cash and cash equivalents were $294.0 million.
- Price Action: CMPS shares up 7.78% at $39.71 during the premarket session on the last check Tuesday.
Loading...
Loading...
CMPSCompass Pathways PLC
$3.86-1.28%
Edge Rankings
Momentum
13.55
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
